Patients with hyperphosphatemia taking an investigational phosphate-binding agent achieved clinical targets with lower pill burden, according to pivotal trial data presented at ASN Kidney Week. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback